SCHEMBL1012956

SCHEMBL1012956

CC(C)(C)c1ccc(-c2cc(Cl)nc(Cl)n2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
KMT2A Q03164 5/20 0.46
MEN1 O00255 4/20 0.46
HPGD P15428 3/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
KDM4E B2RXH2 3/20 0.46
MAPT P10636 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KIF11 P52732 1/20 0.41
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
NPSR1 Q6W5P4 1/20 0.40
HSP90AA1 P07900 2/20 0.40
HSP90AB1 P08238 2/20 0.40
DHODH Q02127 1/20 0.39
TNF P01375 1/20 0.38
NOD1 Q9Y239 1/20 0.38
TDO2 P48775 1/20 0.38
SYK P43405 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29389980 1.00 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1HPGDL3MBTL1
SCHEMBL3624341 0.91 ALDH1A1 (0.55) ALDH1A1KMT2AMEN1HPGDL3MBTL1
SCHEMBL17413751 0.86 NPC1 (0.53) ALDH1A1KMT2AMEN1HPGDL3MBTL1
SCHEMBL10051515 0.84 MEN1 (0.60) ALDH1A1KMT2AMEN1HPGDL3MBTL1
SCHEMBL1013065 0.84 ALDH1A1 (0.42) ALDH1A1KMT2AMEN1HPGDL3MBTL1
SCHEMBL1011410 0.83 HSP90AA1 (0.62) ALDH1A1KMT2AHPGDKDM4EMAPT
SCHEMBL4815491 0.83 NPC1 (0.46) ALDH1A1KMT2AMEN1HPGDL3MBTL1
SCHEMBL4619849 0.82 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1HPGDL3MBTL1
SCHEMBL4816969 0.80 NPC1 (0.39) ALDH1A1KMT2AMEN1HPGDL3MBTL1
SCHEMBL3450627 0.79 KDM4E (0.70) ALDH1A1KMT2AMEN1HPGDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10927118-B2 Inhibitors of influenza virus replication and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2021-02-23 US disclosed
US-20200339564-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2020-10-29 US disclosed
CN-110446711-A INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF SUNSHINE LAKE PHARMA CO LTD 2019-11-12 CN disclosed
US-20190185456-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2019-06-20 US disclosed
CN-108276401-A Inhibitors of influenza viruses replication and application thereof 广东东阳光药业有限公司 2018-07-13 CN disclosed
CN-107759571-A Inhibitors of influenza viruses replication and its application method and purposes 广东东阳光药业有限公司 2018-03-06 CN disclosed
US-8608986-B2 Metal complex, polymer compound and device containing those SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-12-17 US disclosed
EP-2128168-B1 METAL COMPLEX, POLYMER COMPOUND AND DEVICE CONTAINING THOSE SUMITOMO CHEMICAL CO (JP) 2013-11-06 EP disclosed
EP-2128168-B1 METAL COMPLEX, POLYMER COMPOUND AND DEVICE CONTAINING THOSE SUMITOMO CHEMICAL CO (JP) 2013-11-06 EP disclosed
EP-1542692-B1 AMINOPYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN AMGEN INC (US) 2011-01-05 EP disclosed
US-7335672-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2008-02-26 US disclosed
EP-1789413-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS Amgen Inc. (US) 2007-05-30 EP disclosed
US-7053088-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2006-05-30 US disclosed
WO-2006031852-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2006-03-23 WO disclosed
US-20060058308-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2006-03-16 US disclosed
US-20050277646-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2005-12-15 US disclosed
US-20050267163-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2005-12-01 US disclosed
EP-1542692-A1 AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN Amgen Inc. (US) 2005-06-22 EP disclosed
US-20040038969-A1 Vanilloid receptor ligands and their use in treatments AMGEN, INC. 2004-02-26 US disclosed
WO-2003099284-A1 AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN AMGEN INC. (US) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058308-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV3, TRPV2 ALDH1A1 3133/4885KMT2A 3883/4885MEN1 4479/4885
US-10927118-B2 Inhibitors of influenza virus replication and uses thereof EIF2AK2, POLRMT, ZC3HAV1 ALDH1A1 4038/4885KMT2A 2123/4885MEN1 4172/4885
US-20200339564-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF EIF2AK2, ZC3HAV1, MAVS ALDH1A1 3638/4885KMT2A 1921/4885MEN1 4563/4885
US-20190185456-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF POLRMT, EIF2AK2, POLM ALDH1A1 3790/4885KMT2A 1637/4885MEN1 4473/4885
US-20040038969-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 ALDH1A1 3105/4885KMT2A 3770/4885MEN1 3327/4885
US-20050267163-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 ALDH1A1 3238/4885KMT2A 3777/4885MEN1 3504/4885
US-20050277646-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 ALDH1A1 3238/4885KMT2A 3777/4885MEN1 3504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.